Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Expands By 22.9%

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 986,300 shares, an increase of 22.9% from the November 30th total of 802,800 shares. Based on an average trading volume of 525,700 shares, the short-interest ratio is presently 1.9 days. Approximately 1.7% of the shares of the company are sold short.

Institutional Trading of Context Therapeutics

Institutional investors have recently modified their holdings of the business. Y Intercept Hong Kong Ltd purchased a new stake in Context Therapeutics during the third quarter worth about $89,000. Renaissance Technologies LLC lifted its position in shares of Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company's stock valued at $131,000 after acquiring an additional 25,300 shares during the period. State Street Corp boosted its stake in shares of Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company's stock worth $219,000 after acquiring an additional 19,800 shares in the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company's stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the period. Finally, Franklin Resources Inc. purchased a new position in Context Therapeutics in the 3rd quarter valued at approximately $3,689,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CNTX has been the subject of several research reports. D. Boral Capital started coverage on shares of Context Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $9.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $6.00 target price on shares of Context Therapeutics in a research note on Monday, September 23rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Context Therapeutics has an average rating of "Buy" and an average price target of $6.80.

Context Therapeutics Stock Performance

CNTX traded down $0.01 during trading on Tuesday, hitting $1.05. The stock had a trading volume of 1,444,265 shares, compared to its average volume of 363,467. Context Therapeutics has a twelve month low of $0.89 and a twelve month high of $2.75. The company's 50-day moving average price is $1.65 and its 200 day moving average price is $1.97. The firm has a market capitalization of $78.75 million, a P/E ratio of -1.15 and a beta of 2.00.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.11). As a group, equities analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.